医药板块连续三日上涨，关注恒生创新药ETF（159316）、医药ETF（512010）等配置价值

Core Viewpoint - The pharmaceutical sector continues its upward trend, achieving a "three consecutive days of gains" with various indices showing positive growth, indicating a robust market performance in the industry [1]. Group 1: Market Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 1.7% [1]. - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index increased by 1.2% [1]. - The CSI Innovative Drug Industry Index saw a rise of 1.1% [1]. - The CSI Biotechnology Theme Index and the CSI 300 Pharmaceutical and Health Index both grew by 0.6% [1]. Group 2: Industry Insights - CITIC Securities states that the Chinese pharmaceutical industry has entered a critical phase characterized by "innovation realization and global layout" [1]. - Key supports for the industry include population and domestic demand base, as well as comprehensive manufacturing capabilities across the entire industry chain [1]. - Companies are actively exploring diversified overseas paths [1]. - Looking ahead to 2026, opportunities are expected in innovative commercialization, global breakthroughs, policy optimization, and industry mergers and acquisitions [1].